Immunome, Inc. (IMNM)

$ 16.72
-1.12 (-6.28%)
-
Symbol IMNM
Price $ 16.72
Beta 0.000
Volume Avg. 0.17M
Market Cap 0.202B
Shares () -
52 Week Range 9.275-63.78
1y Target Est -
DCF Unlevered IMNM DCF ->
DCF Levered IMNM LDCF ->
ROE -43.02% Strong Sell
ROA -33.46% Strong Sell
Operating Margin -
Debt / Equity 14.17% Neutral
P/E -
P/B 3.64 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IMNM news


Dr. Purnanand Duddu Sarma
Healthcare
Biotechnology
NCM

Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.